Literature DB >> 18579018

Meningiomas.

Sean Grimm1, Jeffrey J Raizer.   

Abstract

Meningiomas, the most common intracranial tumors, are dura-based tumors that occur in middle-aged or older adults and have a predilection for women and African Americans. They are almost always benign, but atypical and malignant forms exist. The optimal treatment for symptomatic tumors is complete surgical resection when feasible. Tumors in poor locations can have a higher rate of morbidity and often can be only partially removed. Radiation therapy should be used to treat lesions that are partially removed and lesions of higher grade, despite complete removal. Small lesions may be amenable to radiosurgery, which may obviate surgery in high-risk patients. For lesions that recur or grow despite surgery and radiation, the only option is systemic chemotherapy. No agent is optimal, but hydroxyurea is used most often. Newer approaches such as the use of inhibitors of somatostatin receptors or signal transduction pathways are under investigation.

Entities:  

Year:  2008        PMID: 18579018     DOI: 10.1007/s11940-008-0034-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  25 in total

Review 1.  Natural history of conservatively treated meningiomas.

Authors:  Z Herscovici; Z Rappaport; J Sulkes; L Danaila; G Rubin
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

2.  Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.

Authors:  S M Grunberg; M H Weiss; I M Spitz; J Ahmadi; A Sadun; C A Russell; L Lucci; L L Stevenson
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

Review 3.  Targeted drug therapy for meningiomas.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

4.  Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.

Authors:  S M Grunberg; M H Weiss
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

5.  Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience.

Authors:  Shigetoshi Yano; Jun-ichi Kuratsu
Journal:  J Neurosurg       Date:  2006-10       Impact factor: 5.115

6.  Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.

Authors:  H B Newton; S R Scott; C Volpi
Journal:  Br J Neurosurg       Date:  2004-10       Impact factor: 1.596

7.  The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.

Authors:  S E Kaba; F DeMonte; J M Bruner; A P Kyritsis; K A Jaeckle; V Levin; W K Yung
Journal:  Neurosurgery       Date:  1997-02       Impact factor: 4.654

8.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

Review 9.  Meningeal tumors of childhood and infancy. An update and literature review.

Authors:  Arie Perry; Louis P Dehner
Journal:  Brain Pathol       Date:  2003-07       Impact factor: 6.508

10.  A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.

Authors:  J W Goodwin; J Crowley; H J Eyre; B Stafford; K A Jaeckle; J J Townsend
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.